Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of “Strong Buy” from Brokerages

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been given an average rating of “Strong Buy” by the six brokerages that are presently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $34.00.

A number of research firms recently issued reports on CPRX. Weiss Ratings reiterated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Friday. Zacks Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Citigroup lifted their target price on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th.

Institutional Trading of Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Hsbc Holdings PLC boosted its holdings in Catalyst Pharmaceuticals by 91.9% in the 4th quarter. Hsbc Holdings PLC now owns 57,929 shares of the biopharmaceutical company’s stock valued at $1,362,000 after purchasing an additional 27,739 shares during the period. Rockefeller Capital Management L.P. increased its holdings in shares of Catalyst Pharmaceuticals by 29.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 29,680 shares of the biopharmaceutical company’s stock worth $693,000 after purchasing an additional 6,752 shares during the period. Invesco Ltd. raised its position in shares of Catalyst Pharmaceuticals by 4.9% in the fourth quarter. Invesco Ltd. now owns 1,293,478 shares of the biopharmaceutical company’s stock worth $30,190,000 after buying an additional 60,221 shares in the last quarter. EP Wealth Advisors LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter worth $630,000. Finally, Mackenzie Financial Corp bought a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at $210,000. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Trading Up 4.1%

Catalyst Pharmaceuticals stock opened at $24.76 on Friday. Catalyst Pharmaceuticals has a 1-year low of $19.05 and a 1-year high of $26.58. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of 14.65, a P/E/G ratio of 0.69 and a beta of 0.75. The firm has a 50 day simple moving average of $24.06 and a 200 day simple moving average of $22.78.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).